TRIANA is conducting a global Phase 1/2 clinical trial investigating TRI-611 for the treatment of adult patients with ALK+ NSCLC. ​

​TRI-611 is an orally available, investigational therapy that is specifically designed to target and degrade ALK fusion proteins, the abnormal proteins that are the underlying cause of tumor growth in patients with ALK+ NSCLC. ​

​The ongoing Phase 1/2 clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of TRI-611 in patients with ALK+ NSCLC.  The Phase 1 portion will consist of a dose escalation design, enrolling ALK+ NSCLC patients, who have been previously treated with standard of care ALK Tyrosine Kinase Inhibitors (ALK TKI) therapies. The Phase 2 portion will further evaluate and characterize the efficacy and safety of TRI-611 at the recommended dose across different patient cohorts.  ​

For more information, visit www.clinicaltrials.gov